Tarık DEMİR, Fikret AKYÜREK, Sedat ABUSOGLU, ALİ ÜNLÜ, Kenan DEMİR, Ahmet AVCI, Sema YİLMAZ

Association between disease activity, asymmetric dimethylarginine, tumor necrosis factor-alpha, interleukin-10 and neopterin with echocardiography and blood pressure monitoring findings in patients with systemic lupus erythematosus

Pulse wave velocity (PWV) and augmentation index (AIx) have been repeatedly showed to be correlated with premature atherosclerosis. The increased arterial stiffness and endothelium dysfunction may cause premature aging of the arteries in patients with systemic lupus erythematosus (SLE). However, the association of PWV and its markers, AIx, has not been linked to SLE Disease Activity Index (SLEDAI), Asymmetric dimethylarginine (ADMA) and inflammatory cytokines in SLE women. 57 women diagnosed with SLE and 31 healthy women were consequently included in the study and both groups were compared according to age, body mass index (BMI), serum lipid profile, creatinine, cardiac parameters, blood pressure. Tumor Necrosis Factor-Alpha (TNF-α), Interleukin 10 (IL-10), neopterin, and ADMA were assayed. In SLE women, PWV was significantly higher (p=0.04), and AIx was not different from controls (p=0.136). In linear multiple stepwise regression analysis, when patients and controls were both considered, PWV was weakly related to age (p=0.001), waist circumference (p=0.003), LDL-cholesterol (p=0.018), ADMA (p=0.042). Although, when the individual SLE setting was analyzed, PWV was not related to organ damage measured by SLEDAI (p=0.4), ADMA (p=0.361), TNF-α (p=0.893), IL-10 (p=0.686), and neopterin (p=(0.444)). PWV was significantly related to mean blood pressure (MBP) (p=0.001), age (p=0.001), disease duration (p=0.001) and glucocorticoid (p=0.014). Our data suggest that controlling MBP and appropriate indications of low doses steroids can partially slow down the process of early atherosclerosis in female patients diagnosed with SLE.

PDF

___

Zardi EM, Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: are they early markers of subclinical atherosclerosis? Autoimmunity reviews 2010;9:684-6.

Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus-role of inflammatory mechanisms. Autoimmunity Reviews 2006;5:101-5.

Westerweel PE, Luyten RK, Koomans HA, et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis & Rheumatology 2007;56:1384-96.

Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity 2010;43:98-102.

Sacre K, Escoubet B, Pasquet B, et al. Increased arterial stiffness in systemic lupus erythematosus (SLE) patients at low risk for cardiovascular disease: a cross-sectional controlled study. PLoS One 2014;9:94511.

Cypiene A, Kovaite M, Venalis A, et al. Arterial wall dysfunction in systemic lupus erythematosus. Lupus 2009;18:522-9.

Perna M, Roman MJ, Alpert DR, et al. Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients. Arthritis & Rheumatology 2010;62:1718-22.

Kiani AN, Mahoney JA, Petri M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. The Journal of rheumatology 2007;34:1502-5.

Bultink IE, Teerlink T, Heijst JA, et al. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Annals of the rheumatic diseases 2005;64:1362-5.

10. Barbulescu A, Vreju F, Cojocaru-Gofita I, et al. Impaired arterial stiffness in systemic lupus erythematosus-correlations with inflammation markers. Current health sciences journal 2012;38:61.

11. Roman MJ, Devereux RB, Schwartz JE, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005;46:194-9.

12. Samsonov MY, Tilz GP, Egorova O, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4:29-32.

13. Lim KL, Muir K, Powell RJ. Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus. Annals of the rheumatic diseases 1994;53:743.

14. Wen C, Fan Y, Li X. Effect of langchuangding on serum soluble interleukin-2 receptor and neopterin level in patients of systemic lupus erythematosus. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi= Chinese journal of integrated traditional and Western medicine 2001;21:339-41.